Aptose Biosciences Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 12 - Stock-based Compensation (Tables)

Note 12 - Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2021

Notes Tables

Share-based Payment Arrangement, Option, Activity [Table Text Block]

Option numbers are in (000’s)
										Weighted average
		Options				Weighted average exercise price				remaining contractual life (years)				Aggregate Intrinsic Value

Outstanding, December 31, 2019			5,941			$	2.84
Granted			6,362				6.81
Exercised			(235	)			2.45
Forfeited			(126	)			4.50
Outstanding, December 31, 2020			11,942			$	4.97
Granted			4,659				3.84
Exercised			(82	)			2.32
Forfeited			(1,407	)			5.38
Outstanding, December 31, 2021			15,112			$	4.61				6.6			$	96,117
Exercisable, December 31, 2021			8,164			$	4.50				5.3			$	96,117
Vested and expected to vest, December 31, 2021			14,068			$	4.60				6.5			$	96,117

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

		Year ended December 31, 2021				Year ended December 31, 2020

Risk-free interest rate			0.59	%			1.27	%
Expected dividend yield			-				-
Expected volatility			81.8	%			85.9	%
Expected life of options (years)		5				5
Grant date fair value		$	2.47			$	4.59

Schedule of Share-based Payment Award, Options, Grants in Period [Table Text Block]

Option numbers are in (000’s)		Year ended December 31, 2021				Year ended December 31, 2020
		Number of options				Number of options
Cliff vesting after one year anniversary			-				300
3 year vesting (50%-25%-25%)			430				862
4 year vesting (50%-16 2/3%-16 2/3%-16 2/3%)			3,429				5,200
Earlier of Performance criteria or 4 years			800				-
Total stock options granted in the year			4,659				6,362

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

		Year ended, December 31, 2021								Year ended, December 31, 2020
		Number (in thousands)				Weighted average grant date fair value				Number (in thousands)				Weighted average grant date fair value
Outstanding, beginning of period			-			$	-				40			$	2.00
Granted			-				-				645				7.32
Vested			-				-				(685	)			7.01
Outstanding, end of period			-			$	-				-			$	-

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

		Year ended December 31, 2021				Year ended December 31, 2020

Research and development		$	3,789			$	3,720
General and administrative			9,160				17,718
Total		$	12,949			$	21,438